Novozymes improves plectasin and discovers new AMPs  

Denmark's Novozymes which last year announced the sensational discovery of an antimicrobial peptide, is growing a new AMP business area

Since Denmark's Novozymes last autumn announced the sensational discovery of plectasin, an antimicrobial peptide (AMP) active against multi-resistant bacteria that pose a threat to global health, the company has not only improved the substance, but has also discovered other antimicrobial peptides in other organisms. Plectasin was discovered in a black mushroom, Pseudoplectania nigrella, which grows in coniferous forests in northern Europe.

Novozymes has established a new business area, the AMP department, headed by Søren Kjærulff who says: "In addition to improving the substance from the mushroom, the good news is that we have also discovered other antimicrobial peptides in other organisms. They are all being improved and tested." Some of the new AMPs Novozymes has discovered are active against Gram-negative* bacteria.

Novozymes is the biotech-based world leader in enzymes and microorganisms. Headquartered in Bagsværd near Copenhagen, the company employs 4,000 people, half of whom are employed in Denmark. Novozymes' 700 products are a key factor in the production of thousands of products used in everyday life. The company's B shares are listed on Copenhagen Stock Exchange.

The news was reported by professional journal Ingeniøren (The Engineer).

*Many species of Gram-negative bacteria are pathogenic – Ed.

Link > Novozymes 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×